Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Total Current Liabilities (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed Total Current Liabilities for 16 consecutive years, with $6.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Current Liabilities rose 39.13% year-over-year to $6.6 million, compared with a TTM value of $6.6 million through Sep 2025, up 39.13%, and an annual FY2024 reading of $5.0 million, down 26.44% over the prior year.
  • Total Current Liabilities was $6.6 million for Q3 2025 at China Pharma Holdings, up from $5.3 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $12.7 million in Q4 2022 and bottomed at $4.7 million in Q2 2024.
  • Average Total Current Liabilities over 5 years is $8.5 million, with a median of $8.4 million recorded in 2022.
  • The sharpest move saw Total Current Liabilities crashed 55.32% in 2024, then skyrocketed 39.13% in 2025.
  • Year by year, Total Current Liabilities stood at $10.5 million in 2021, then increased by 21.17% to $12.7 million in 2022, then plummeted by 46.46% to $6.8 million in 2023, then fell by 26.44% to $5.0 million in 2024, then surged by 32.0% to $6.6 million in 2025.
  • Business Quant data shows Total Current Liabilities for CPHI at $6.6 million in Q3 2025, $5.3 million in Q2 2025, and $5.1 million in Q1 2025.